Sevelamer attenuates the progression of coronary and aortic @entity730 in hemodialysis XXXX .

@entity1 @entity2741 @entity730 @entity1391 @entity461 @entity460 @entity209 @entity3151 @entity65 @entity454
BACKGROUND: @entity65 is frequent and severe in @entity1 with @entity454 . @entity209 may contribute by promoting @entity65 . METHODS: We conducted a randomized clinical trial comparing sevelamer, a non-absorbed polymer, with @entity460 -based @entity1391 binders in 200 hemodialysis @entity1 . Study outcomes included the targeted concentrations of serum @entity3151 , @entity460 , and intact @entity461 ( @entity461 ), and @entity730 of the coronary arteries and thoracic aorta using a @entity730 score derived from electron beam tomography. RESULTS: Sevelamer and @entity460 provided equivalent control of serum @entity3151 (end-of-study values 5.1 +/- 1.2 and 5.1 +/- 1.4 mg/dL, respectively, P = 0.33). Serum @entity460 concentration was significantly higher in the @entity460 -treated group (P = 0.002), and @entity2741 was more common (16% vs. 5% with sevelamer, P = 0.04). More subjects in the @entity460 group had end-of-study intact @entity461 below the target of 150 to 300 pg/mL (57% vs. 30%, P = 0.001). At study completion, the median absolute @entity460 score in the coronary arteries and aorta increased significantly in the @entity460 treated subjects but not in the sevelamer-treated subjects (coronary arteries 36.6 vs. 0, P = 0.03 and aorta 75.1 vs. 0, P = 0.01, respectively). The median percent change in coronary artery (25% vs. 6%, P = 0.02) and aortic (28% vs. 5%, P = 0.02) @entity460 score also was significantly greater with @entity460 than with sevelamer. CONCLUSIONS: Compared with @entity460 -based @entity1391 binders, sevelamer is less likely to cause @entity2741 , low levels of @entity461 , and progressive coronary and aortic @entity730 in hemodialysis @entity1 .
